No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers

Breast Cancer Research and Treatment

Volumn 115, Issue 2, 2009, Pages 307-313

  Spurdle, Amanda B ^a,b   Deans, Andrew J ^b   Duffy, David ^a   Goldgar, David E ^c   Chen, Xiaoqing ^a   Beesley, Jonathan ^a   Easton, Douglas F ^d   Antoniou, Antonis C ^d   Peock, Susan ^d   Cook, Margaret ^d   Nathanson, Katherine L ^e   Domchek, Susan M ^e   MacArthur, Grant A ^b,f   Chenevix Trench, Georgia ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f University of Cambridge ^*  (Australia)

Author keywords

BRCA1; BRCA2; Modifier; P27

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B;

ALLELE; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER RISK; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM; UNITED STATES;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 67349250407     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0083-5     Document Type: Article

References (32)

1. A Antoniou PD Pharoah S Narod 2003 Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 1117 1130 10.1086/375033
2. N Turner A Tutt A Ashworth 2004 Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 814 819 10.1038/nrc1457
3. PO Chappuis L Kapusta LR Begin 2000 Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer J Clin Oncol 18 4045 4052
4. Y Niwa T Oyama T Nakajima 2000 BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers Jpn J Cancer Res 91 519 526
5. WD Foulkes JS Brunet IM Stefansson 2004 The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer Cancer Res 64 830 835 10.1158/0008-5472.CAN-03-2970
6. RV Lloyd LA Erickson L Jin 1999 p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers Am J Pathol 154 313 323
7. Y Yuan L Qin D Liu 2007 Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression Cancer Res 67 8032 8042 10.1158/0008-5472.CAN-07-0083
8. AJ Deans KJ Simpson MK Trivett MA Brown GA McArthur 2004 Brca1 inactivation induces p27(Kip1)-dependent cell cycle arrest and delayed development in the mouse mammary gland Oncogene 23 6136 6145 10.1038/sj.onc.1207805
9. EA Davison CS Lee MJ Naylor 2003 The CDK inhibitor p27 (Kip1) regulates both DNA synthesis and apoptosis in mammary epithelium but is not required for its functional development during pregnancy Mol Endocrinol 17 2536 2547
10. ML Fero M Rivkin M Tasch 1996 A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice Cell 85 733 744 10.1016/S0092-8674(00)81239-8
11. ML Fero E Randel KE Gurley JM Roberts CJ Kemp 1998 The murine gene p27Kip1 is haplo-insufficient for tumour suppression Nature 396 177 180 10.1038/24179
12. BL Chang SL Zheng SD Isaacs 2004 A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer Cancer Res 64 1997 1999 10.1158/0008-5472.CAN-03-2340
13. P Gonzalez A Diez-Juan E Coto 2004 A single-nucleotide polymorphism in the human p27kip1 gene (-838C > A) affects basal promoter activity and the risk of myocardial infarction BMC Biol 2 5 10.1186/1741-7007-2-5
14. TC Chen KF Ng JM Lien LB Jeng MF Chen LL Hsieh 2000 Mutational analysis of the p27(kip1) gene in hepatocellular carcinoma Cancer Lett 153 169 173 10.1016/S0304-3835(00)00366-9
15. AS Kibel BK Suarez J Belani 2003 CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma Cancer Res 63 2033 2036
16. Guo W, Cui YJ, Fang SM, Li Y, Wang N, Zhang JH (2006) Association of polymorphisms of p21cip1 and p27kip1 genes with susceptibilities of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. Ai Zheng 25:194-199
17. G Li EM Sturgis LE Wang 2004 Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma Clin Cancer Res 10 3996 4002 10.1158/1078-0432.CCR-04-0089
18. H Tigli N Buyru N Dalay 2005 Molecular analysis of the p27/kip1 gene in breast cancer Mol Diagn 9 17 21 10.2165/00066982-200509010-00003
19. R Naidu YC Har NA Taib 2007 P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer J Exp Clin Cancer Res 26 133 140
20. T Schondorf L Eisele UJ Gohring 2004 The V109G polymorphism of the p27 gene CDKN1B indicates a worse outcome in node-negative breast cancer patients Tumour Biol 25 306 312 10.1159/000081396
21. JC Figueiredo JA Knight S Cho 2007 Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis BMC Cancer 7 99 10.1186/1471-2407-7-99
22. FJ Couch O Sinilnikova RA Vierkant 2007 AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study Cancer Epidemiol Biomarkers Prev 16 1416 1421 10.1158/1055-9965.EPI-07-0129
23. AC Antoniou AB Spurdle OM Sinilnikova 2008 Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers Am J Hum Genet 82 1 12
24. DE Goldgar DF Easton AM Deffenbaugh AN Monteiro SV Tavtigian FJ Couch 2004 Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2 Am J Hum Genet 75 535 544 10.1086/424388
25. G Chenevix-Trench S Healey S Lakhani 2006 Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance Cancer Res 66 2019 2027 10.1158/0008-5472.CAN-05-3546
26. J Beesley SJ Jordan AB Spurdle 2007 Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set Cancer Epidemiol Biomarkers Prev 16 2557 2565 10.1158/1055-9965.EPI-07-0542
27. Huber PJ (1967) The behaviour of maximum likelihood estimates under non-standard conditions. Fifth Berkeley symposium in mathematical statistics and probability. University of California Press, Berkeley, California, pp 221-233
28. AC Antoniou DE Goldgar N Andrieu 2005 A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes Genet Epidemiol 29 1 11 10.1002/gepi.20074
29. Sinnwell JP, Schaid DJ, Yu Z (2007) Haplo.stats: statistical analysis of haplotypes with traits and covariates when linkage phase is ambiguous. R package. 1.3.0 ed
30. PO Chappuis L Kapusta LR Begin 2000 Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer J Clin Oncol 18 4045 4052
31. PL Porter WE Barlow IT Yeh 2006 p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy J Natl Cancer Inst 98 1723 1731
32. IM Chu L Hengst JM Slingerland 2008 The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy Nat Rev Cancer 8 253 267 10.1038/nrc2347